Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial

Blood (2024) 144 (Supplement 1): 5592.

https://doi.org/10.1182/blood-2024-202164

Published: 2024

Journal Articles

Tracking Entire Units of Transfused Pathogen-Reduced Red Cells in Sickle Cell Patients Using a Novel Acridine Marker

Richard J Benjamin, John Pitman, Christopher Karim, Anna Erickson, Laurence Corash, Nina Mufti, Patricia Elizabeth Zerra, Ross M. Fasano, Marianne Yee

Blood (2024) 144 (Supplement 1): 2501.

https://doi.org/10.1182/blood-2024-201726

Published: 2024

Journal Articles

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) and Cryoprecipitated AHF Contain Von Willebrand Factor with Comparable Binding to Collagen and Support Shear-Induced Platelet Thrombus Formation

Subramanian Yegneswaran, Alessandro Zarpellon, Jennifer N Orje, Michelle Gatmaitan, Nina Mufti, Laurence Corash, Zaverio M Ruggeri

Blood (2023) 142 (Supplement 1): 4039.

https://doi.org/10.1182/blood-2023-187124

Published: 2023

Journal Articles

Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study

Allison P. Wheeler, Edward L. Snyder, Majed A. Refaai, Claudia S. Cohn, Jessica Poisson, Magali J. Fontaine, Mary Sehl, Ajay K. Nooka, Lynne Uhl, Philip C. Spinella, Maly Fenelus, Darla Liles, Thomas Coyle, Joanne Becker, Michael R. Jeng, Kathy Liu, Richard J Benjamin, Laurence Corash

Blood (2021) 138 (Supplement 1): 1077.

https://doi.org/10.1182/blood-2021-146916

Published: 2021

Journal Articles

Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136180

Published: 2020

Journal Articles

Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis

Andreas S. Buser, MD, Laura Infanti, MD, Andreas Holbro, MD, Joerg Halter, MD, Sabine Gerull, MD, Dominik Heim, MD, Michael Medinger, MD, Dimitrios A. Tsakiris, MD, Johannes Irsch, PhD, Jin-Sying Lin, PhD, Richard J. Benjamin, MD, Laurence Corash, MD, Jakob R. Passweg, MD

Blood (2019) 134 (Supplement_1): 1167.

https://doi.org/10.1182/blood-2019-122330

Published: 2019

Journal Articles

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

Yesim Aydinok, Antonio Piga, Raffaella Origa, MD, Nina Mufti, PhD, Anna Erikson, PhD, Anne North, PhD, Katie Waldhaus, Christine Ernst, MD, Jin-Sying Lin, PhD, Norman Huang, PhD, Richard J. Benjamin, MD, Laurence Corash, MD

Blood (2018) 132 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2018-99-112685

Published: 2018

Journal Articles

A Sequential Cohort Study of Pathogen Reduced Platelet Component Transfusion without Use of Leukocyte Reduction for Hematopoietic Stem Cell Transplant (HSCT): Impact on Clinical Refractoriness

Laurence Corash, MD, Joycelyn Sim, MDMBBS, Wai-Chiu Tsoi, MD, Cheuk Kwong Lee, MD, Rock Y.Y. Leung, MD, Yingjie Liu, MD, Norman Huang, PhD, Clarence C.K. Lam, Hans Vermeij, Adonis Stassinopoulos, PhD BSc, MPhil, MA, Richard J. Benjamin, MD, Albert Kwok Wai Lie, MBBS,FRCP,FRCPath,FRCPA

Blood (2018) 132 (Supplement 1): 1257.

https://doi.org/10.1182/blood-2018-99-112305

Published: 2018

Journal Articles

Pathogen Inactivated Platelet Components Used without Leukofiltration, or Gamma Irradiation Show Comparable Therapeutic Efficacy and Safety to Gamma Irradiated and Non-Leukofiltered Conventional Products for the Support of HSCT Patients in Hong Kong

Joycelyn Sim Pui Yin, Rock Leung Yuk Yan, Clarence Lam Chun Kit, Chiu Tsoi Wai, Kwong Lee Cheuk, Albert Lie Kwok Wai, Norman Huang, Salvador Rico, Jin-Sying Lin, Laurence Corash, Adonis Stassinopoulos

Blood (2016) 128 (22): 1454.

https://doi.org/10.1182/blood.V128.22.1454.1454

Published: 2016

Journal Articles

Treatment Use Study of Platelet Components Treated with Amotosalen and Ultraviolet a Light in Response to Emerging Arboviruses in Puerto Rico - True Study Final Results

Salvador Rico, Susan L. Stramer, PhD, Richard J. Benjamin, MD PhD, Edgardo Cartagena, Axel Arroyo, Nelson Robles, Simon Carlo, L Vera, P Solivan-Ortiz, Norman Huang, Claudia Koontz, Travis Berry, Laurence Corash

Blood (2016) 128 (22): 3844.

https://doi.org/10.1182/blood.V128.22.3844.3844

Published: 2016

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

Assessing the Efficacy of RBC Component Transfusion Therapy in Patients with Thalassemia Major

William F. Reed, MD, Claire Sherman, Filomena Longo, Marianna Genisio, Laurence Corash, MD, Renzo Galanello, MD, Antonio Piga, MD

Blood (2012) 120 (21): 1185.

https://doi.org/10.1182/blood.V120.21.1185.1185

Published: 2012

Journal Articles

Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance.

Laurence Corash, MD

Blood (2012) 120 (21): 2278.

https://doi.org/10.1182/blood.V120.21.2278.2278

Published: 2012

Journal Articles

Determination of acute lung injury after repeated platelet transfusions

Laurence Corash, Jin Sying Lin, Claire D. Sherman, Joseph Eiden

Blood (2011) 117 (3): 1014–1020.

https://doi.org/10.1182/blood-2010-06-293399

Published: 2011

Includes: Supplemental data

Journal Articles

Prevention of Transfusion-Associated Graft Versus Host Disease (TA-GVHD) by Photochemical Treatment of Platelet Components: Clinical Experience in Routine Use.

Jean Claude Osselaer, MD, JD, Chantal Doyen, MD, Carlos Graux, MD, Christian Chatelain, MD, Anne Sonnet, MD, Michele Jacquet, MS, Jin Sying Lin, PhD, Laurence Corash, MD, Andre Bosly, MD, PhD

Blood (2007) 110 (11): 2885.

https://doi.org/10.1182/blood.V110.11.2885.2885

Published: 2007

Journal Articles

Coagulation Factor Activity in Therapeutic Plasma Prepared from Whole Blood with Pathogen Inactivation (INTERCEPT ™ ) Treatment.

Jean-Pierre Cazenave, Hervé Isola, Marie-Louise Wiesel, Daniel Kientz, Michel Laforêt, Linda Pinkoski, Yasmin Singh, Laurence Corash

Blood (2006) 108 (11): 4149.

https://doi.org/10.1182/blood.V108.11.4149.4149

Published: 2006

Journal Articles

Coagulation Factors in Therapeutic Apheresis Plasma Held for 18 Hours at Ambient Temperature Prior to Pathogen Inactivation (INTERCEPT™).

Jean-Pierre Cazenave, Hervé Isola, Marie-Louise Wiesel, Daniel Kientz, Michel Laforêt, Marc Slaedts, Linda Pinkoski, Yasmin Singh, Laurence Corash

Blood (2006) 108 (11): 940.

https://doi.org/10.1182/blood.V108.11.940.940

Published: 2006

Journal Articles

Release of Immune Modulation Factors from Platelet Concentrates during Storage after Photochemical Pathogen Inactivation.

Laurence Corash, MD, Fabrice Cognasse, PhD, Jean-Claude Osselaer, MD, JD, Natalie Messe, Olivier Garraud, MD, PhD

Blood (2006) 108 (11): 941.

https://doi.org/10.1182/blood.V108.11.941.941

Published: 2006

Journal Articles

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Markus M. Mueller, MD, Hans-Ulrich Pfeiffer, Margaret Rheinschmidt, PhD, Bernd Poetzsch, MD, PhD, Johannes Oldenburg, MD, PhD, Laurence Corash, MD, PhD, Erhard Seifried, MD, PhD, Reinhard Henschler, MD, PhD

Blood (2006) 108 (11): 942.

https://doi.org/10.1182/blood.V108.11.942.942

Published: 2006

Journal Articles

Cytokines in Platelet Components Associated with Acute Transfusion Reactions: The Role of sCD40L.

Laurence Corash, MD, Fabrice Cognasse, PhD, Jean-Claude Osselaer, MD, JD, Natalie Messe, Maryse Van Hooydonk, RN, Olivier Garraud, MD, PhD

Blood (2006) 108 (11): 952.

https://doi.org/10.1182/blood.V108.11.952.952

Published: 2006

NARROW

Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial

Tracking Entire Units of Transfused Pathogen-Reduced Red Cells in Sickle Cell Patients Using a Novel Acridine Marker

Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) and Cryoprecipitated AHF Contain Von Willebrand Factor with Comparable Binding to Collagen and Support Shear-Induced Platelet Thrombus Formation

Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study

Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study

Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis

Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC)

A Sequential Cohort Study of Pathogen Reduced Platelet Component Transfusion without Use of Leukocyte Reduction for Hematopoietic Stem Cell Transplant (HSCT): Impact on Clinical Refractoriness

Pathogen Inactivated Platelet Components Used without Leukofiltration, or Gamma Irradiation Show Comparable Therapeutic Efficacy and Safety to Gamma Irradiated and Non-Leukofiltered Conventional Products for the Support of HSCT Patients in Hong Kong

Treatment Use Study of Platelet Components Treated with Amotosalen and Ultraviolet a Light in Response to Emerging Arboviruses in Puerto Rico - True Study Final Results

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Assessing the Efficacy of RBC Component Transfusion Therapy in Patients with Thalassemia Major

Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance.

Determination of acute lung injury after repeated platelet transfusions

Prevention of Transfusion-Associated Graft Versus Host Disease (TA-GVHD) by Photochemical Treatment of Platelet Components: Clinical Experience in Routine Use.

Coagulation Factor Activity in Therapeutic Plasma Prepared from Whole Blood with Pathogen Inactivation (INTERCEPT ™ ) Treatment.

Coagulation Factors in Therapeutic Apheresis Plasma Held for 18 Hours at Ambient Temperature Prior to Pathogen Inactivation (INTERCEPT™).

Release of Immune Modulation Factors from Platelet Concentrates during Storage after Photochemical Pathogen Inactivation.

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Cytokines in Platelet Components Associated with Acute Transfusion Reactions: The Role of sCD40L.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only